Azithromycin: 1.0 or 3.0 Gram Dose in the Treatment of Patients with Asymptomatic Urogenital Chlamydial Infections

Topić, Antea; Skerk, V.; Puntarić, Alemka; Puretic, V. Milavec; Beus, Antun; Begovać, Josip

doi:10.1179/joc.2006.18.1.115

Cited by 1 publication

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, the majority of the studies included males only 16–18 24 26 27. Two studies included female patients19 25 and three studies included both males and females 22 23 28. One retrospective study compared outcomes in pregnant patients 25.…”

Section: Resultsmentioning

confidence: 99%

“…One retrospective study compared outcomes in pregnant patients 25. For diagnostic methods, six studies used the GenProbe Aptima Combo 2 assay for diagnosis of chlamydia,16–19 23 27 four used other molecular diagnostic tests24–26 28 and one older study used McCoy tissue culture 22…”

Section: Resultsmentioning

confidence: 99%

“…Takahashi et al conducted a single-arm prospective study of extended release azithromycin 2 g orally single dose and reported a rate of microbiological cure of CT of 91.5%, but 35% of patients experienced diarrhoea which resolved (on its own) within 1 day 27. Topic et al compared azithromycin 1 g orally single dose given weekly for three doses, with azithromycin 1 g orally single dose and found no additional benefit (such as tolerability) to the higher total dose 22. Unemo et al examined the effects of a 5-day azithromycin treatment (500 mg orally on day 1, followed by 250 mg orally daily for 4 days) and found it 98.8% effective; however, no CIs were reported 28…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Non-standard treatment for uncomplicatedChlamydia trachomatisurogenital infections: a systematic review

et al. 2018

View full text Add to dashboard Cite

ObjectivesTo review the literature for non-standard treatment options for uncomplicated Chlamydia trachomatis (CT) infections in adolescents and adults.DesignSystematic review.Data sourcesOvid MEDLINE/PubMed, Ovid EMBASE, Cochrane Trials & Systematic Review Databases, CINAHL Plus with Full Text, Web of Science Core Collection, Scopus, ProQuest Dissertations & Theses Global, ClinicalTrials.gov and Health Canada Trials Database were searched for studies in English or French from 1 January 2006 to 6 August 2017. Keywords included CT, anti-infective or anti-bacterial agents, therapy/pharmacotherapy/management.Review methodsIncluded were primary research studies. Outcome measures included clinical or microbiological cure, treatment failure and adverse events. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were assessed for risk of bias using the Revised Cochrane Risk of Bias V.2.0 tool for randomised and the Newcastle-Ottawa Quality Assessment Scale for non-randomised studies.Funding sourcePublic Health Agency of Canada.ResultsOf the 6899 records identified through the database search, 11 studies were included. One randomised controlled trial reported that delayed release doxycycline was non-inferior to azithromycin. Two studies examined higher doses of azithromycin but reported no additional benefit. One study looked at a 5-day azithromycin treatment regimen and reported a high cure rate. Two studies reported efficacy of sitafloxacin, and a single study supports the use of levofloxacin. Two phase 2 studies reported efficacy of single-dose rifalazil in both men and women. Only one retrospective study was identified that examined treatment in pregnant women and reported that efficacy with single-dose azithromycin exceeded that of amoxicillin and erythromycin. A single study examining the efficacy of a beta-lactam antibiotic was stopped early due to high treatment failures.ConclusionsThe paucity of existing data highlights the need for further adequately powered studies to evaluate rifalazil, delayed release doxycycline, levofloxacin and other agents for the treatment of uncomplicated CT infections.PROSPERO registration numberCRD42017073096.

show abstract